In this high-stakes episode of Global Market Bulletin TV, NEXGEL (NASDAQ: NXGL) CEO, President, and Director Adam Levy sits down with host Leyla Gulen to reveal breakthroughs that could position the company at the forefront of next-generation drug delivery. What he shares in this exclusive interview is already creating major buzz across biotech and investor circles.
Mr. Levy unveils the highly encouraging proof-of-concept results from NEXGEL’s new diclofenac hydrogel patches—an innovation that could disrupt the multi-billion-dollar pain management market. But the surprises don’t stop there. He also reveals progress on NEXGEL’s advanced hydrogel eye patch for amblyopia, a non-invasive alternative for treating “lazy eye” that could transform pediatric vision care worldwide.
The conversation turns personal as Levy shares how his unconventional path—from investment banking to the helm of Warlock Records—shaped his leadership and appetite for innovation. With experience spanning M&A, capital markets, consumer products, media, and direct-to-consumer strategies, Levy explains why NEXGEL is uniquely positioned for explosive growth in the coming months and years.
About the Guest: Adam Levy (CEO, President & Director, NEXGEL)
With a powerhouse background in mergers and acquisitions, corporate finance, capital raising, business development, marketing, and operations, Adam Levy has built a reputation as a visionary leader with the ability to scale companies rapidly. Armed with a Business Administration degree from UC Berkeley and an MBA from the Stanford Graduate School of Business, he has led multiple turnarounds and ambitious growth initiatives across industries.
Levy’s career includes launching hit records at Warlock Records, building consumer brands, steering digital and traditional media campaigns, and raising capital for high-growth ventures. As an angel investor, nonprofit advocate, and mentor, his influence extends far beyond the boardroom. Under his leadership, NEXGEL has strengthened its leadership bench, expanded its product pipeline, and delivered meaningful gains in revenue, profitability, and market share. His strategic vision continues to position the company to capitalize on emerging trends across medical, cosmetic, and consumer-health markets.
CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.
About NEXGEL (NASDAQ: NXGL)
NEXGEL is redefining what’s possible in healthcare and consumer wellness through its gentle, ultra-high-water-content hydrogels—technologies trusted for over two decades. Based in Langhorne, Pennsylvania, the company has engineered more than 200 proprietary hydrogel formulations using electron-beam cross-linking, creating patches designed for comfort, durability, and precise ingredient delivery.
Hydrogels’ unique ability to hold water while delivering drugs, nutrients, or cosmetic agents makes them one of the most versatile materials in modern medicine. From wound care and pain management to dermatology, transdermal delivery, OTC consumer products, and cosmetics, NEXGEL’s innovations are shaping the future of how therapies and wellness solutions reach the body.
READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.
